Leronlimab could have been equally life saving for for patients with multiple drug resistance in HIV, yet the FDA still dragged their feet. While I hope for patients (and my portfolio) this is not the case for cancer, it may be to some degree or another. It’s only mid January, so there is still plenty of time in 2020, but I would not be surprised or disappointed if it happens in 2021